Bevacizumab Treatment After Surgery for Proliferative Diabetic Retinopathy
A Study in Patients Undergoing Vitrectomy
Led by Christian Ophthalmic Surgery Expedition Network · Updated on 2025-03-28
150
Participants Needed
1
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the effects of immediate postoperative bevacizumab administration in patients with proliferative diabetic retinopathy undergoing vitrectomy surgery. The study focuses on individuals with type I or II diabetes who require surgery to address complications such as non-clearing vitreous hemorrhage, tractional retinal detachment, or fibrovascular proliferation affecting vision. The goal is to compare outcomes between those who receive bevacizumab right after surgery and those who do not.
Participants will be randomly assigned to one of two groups one group will receive an injection of bevacizumab immediately after their vitrectomy, while the other group will not receive this treatment. The surgery involved is pars plana vitrectomy, performed to improve vision affected by the diabetic eye complications. This is a double-blind study, meaning neither the participants nor the researchers know who receives the drug or not during the trial.
During the study, participants will be followed and assessed for six months after surgery. Researchers will monitor their vision using tests such as the best-corrected spectacle visual acuity on the Snellen chart. They will also evaluate the safety and effectiveness of the treatment, looking for any changes or complications. Participants will attend scheduled visits to support ongoing monitoring and outcome measurement over this period.
Able and willing to participate with 6 months of follow-up
Diagnosed with type I or II Diabetes Mellitus with active proliferative diabetic retinopathy in the study eye
Best-corrected visual acuity between 20/40 and hand motion in the study eye
Requires pars plana vitrectomy due to non-clearing vitreous hemorrhage present for at least 3 months, threatening or fovea-involving tractional retinal detachment, or extensive threatening fibrovascular proliferation
Only one eye per patient is eligible for the study
You will not qualify if you...
Presence of significant retinal or optic nerve diseases unrelated to diabetes that reduce vision by two or more lines
Significant corneal opacity causing vision loss by two or more lines
Previous vitrectomy surgery in the study eye
Uncontrolled neovascular glaucoma with intraocular pressure over 30 mmHg despite treatment
Uncontrolled hypertension with systolic over 200 mmHg or diastolic over 120 mmHg despite multiple medications
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Surgery and Immediate Post-operative Care
Duration - Day of surgery
Participants undergo pars plana vitrectomy surgery and may receive intravitreal bevacizumab immediately after surgery depending on their group assignment.
1 visit (in-person)
Post-operative Follow-up
Duration - Up to 6 months
Participants are monitored for outcomes and recovery following surgery and any postoperative treatment.
Follow-up visits over 6 months
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Preoperative Bevacizumab Administration in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: A Randomized and Controlled Trial Comparing Interval Variation.